

EYE ON EQUITIES

STOCKS THAT SHOULD BE ON YOUR RADAR SCREEN

ANGELA BARNES
February 28, 2008

ALLON THERAPEUTICS:

(NPC-TSX)

Yesterday's close \$1.15, up 35¢

Results from **Allon Therapeutics Inc.**'s Phase IIa study on its lead drug for patients with amnesic mild cognitive impairment were much stronger than had been expected, said analyst Neil Maruoka of Canaccord Adams. He said the positive indication of the drug's efficacy could attract a partner.

Upside: He boosted his price target to \$3.35 from \$1.90 and maintained his "buy" rating on the shares.
